XENON® is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. We apply our expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Location: Canada, British Columbia, Burnaby
Employees: 51-200
Phone: +1 604-484-3300
Total raised: $265M
Investors 4
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Avoro Capi... | avorocapit... |
| - | InterWest ... | interwest.... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.06.2022 | - | $250M | - |
| 30.01.2022 | - | $15M | - |
Mentions in press and media 17
| Date | Title | Description | Source |
| 12.03.2024 | Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS ... | VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:X... | einpresswi... |
| 05.03.2024 | Xenon Pharmaceuticals to Present at Leerink Partners Global ... | - | globenewsw... |
| 22.06.2022 | Xenon Pharmaceuticals Announces Pricing of $250.0 Million Pu... | BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE... | globenewsw... |
| 12.01.2022 | Xenon Pharmaceuticals : Announces Collaboration with Neurocr... | Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Reg... | marketscre... |
| 12.01.2022 | Xenon Pharmaceuticals Announces Collaboration with Neurocrin... | Xenon Pharmaceuticals Inc. announced that its collaboration to develop treatments for epilepsy with ... | marketscre... |
| 12.01.2022 | Xenon Pharmaceuticals Announces Collaboration with Neurocrin... | BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE... | marketscre... |
| 12.01.2022 | Xenon Pharmaceuticals Announces Collaboration with Neurocrin... | BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE... | globenewsw... |
| 08.10.2021 | Xenon Pharmaceuticals Announces Closing of $345 Million Publ... | BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE... | marketscre... |
| 08.10.2021 | Xenon Pharmaceuticals : Announces Closing of $345 Million Pu... | BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE... | marketscre... |
| 06.10.2021 | Xenon Pharmaceuticals : Announces Pricing of $300.0 Million ... | BURNABY, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE... | marketscre... |
Show more